Madrigal Pharmaceuticals, Inc.
MDGL
$425.85
-$9.77-2.24%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 38.12% | 44.26% | 44.77% | 11.86% | -24.69% |
| Total Depreciation and Amortization | 330.29% | 258.74% | 114.61% | 138.70% | 107.97% |
| Total Amortization of Deferred Charges | -23.22% | -31.44% | -30.74% | -29.06% | -13.46% |
| Total Other Non-Cash Items | 26.96% | 22.02% | 14.46% | 37.89% | 59.81% |
| Change in Net Operating Assets | 88.25% | 287.85% | -716.72% | -1,217.35% | -2,108.33% |
| Cash from Operations | 58.39% | 62.74% | 31.53% | -1.54% | -40.51% |
| Capital Expenditure | 68.06% | 54.32% | 47.72% | 38.65% | 1.15% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 112.01% | 92.81% | 88.74% | 3.87% | 45.53% |
| Cash from Investing | 111.78% | 92.66% | 88.51% | 4.16% | 45.40% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -94.82% | -95.99% | -96.85% | -84.35% | 38.57% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -65.18% | -77.68% | -96.88% | -84.77% | 23.52% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,835.03% | -64.12% | -173.01% | -185.20% | 102.20% |